STOCKHOLM, Sweden — New data on clazakizumab, a monoclonal antibody targeting interleukin-6 , and home hemodialysis suggest the potential of two ways to reduce the high risk for cardiovascular events in people receiving dialysis, according to presentations at the 61st European Renal Association Congress.
The patients had been on hemodialysis for at least 12 weeks and their median baseline serum high-sensitivity C-reactive protein was 8.3 md/dL. The most common cause of kidney failure was diabetes . The patients had a mean age of 62 years; 33% were women, and 46% were non-White. Consistent with an anti-inflammatory effect, small increases in total cholesterol were observed in all three clazakizumab groups.
"Yet, even with these quite low doses of clazakizumab, there was dramatic reduction, not only in CRP but in the downstream biomarkers of IL-6 activity, that was sustained over time," he said."I've been caring for patients on dialysis for the better part of 30 years, and I very rarely even over the course of 6 months let alone 3 months seen an increase in the serum albumin ," he said.
He explained that statins may not be of benefit in patients on dialysis in preventing cardiovascular events owing to a compromised response to those therapies.The study results indicate that"targeting that residual inflammatory risk may improve outcomes and improve quality of life in this high-risk patient group," he said.
Vascular Access Kidney Dialysis Renal Dialysis Haemodialysis Home Dialysis Home Hemodialysis Home Haemodialysis Dialysis Peritoneal Dialysis Renal Failure Renal Insufficiency Kidney Insufficiency Kidney Failure Renal Impairment Renal Disease Kidney Disease Kidney Disorder Renal Disorder Nephropathy CV Risk Cardiovascular Risk CV Risk Factors
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Medscape - 🏆 386. / 55 Read more »
Source: Medscape - 🏆 386. / 55 Read more »
Source: Medscape - 🏆 386. / 55 Read more »
Source: mercnews - 🏆 88. / 68 Read more »
Source: Newsweek - 🏆 468. / 52 Read more »
Source: ScienceDaily - 🏆 452. / 53 Read more »